For liver-protective treatment as described by the patient, it is generally important to distinguish whether the patient has mild liver impairment or has the possibility of liver insufficiency or liver failure. If the elevation of glutathione transaminase is only elevated and the patient’s elevation is not severe, it is recommended that the patient can consider oral liver-protective drugs for liver-protective treatment, which generally does not require hospitalization. Such as hepatoprotective tablets, liver protection tablets and Kexilai tablets for active oral treatment, the patient’s liver function will gradually recover in about 10 days. In addition, for patients with liver insufficiency or liver failure due to viral hepatitis or cirrhosis, as well as for patients with elevated bilirubin, patients should actively consider intravenous infusion of hepatoprotective drugs for hepatoprotective treatment. Such as Mennen, reduced glutathione, hepatopoietin and other drugs, generally patients need active intravenous infusion for about 5-10 days, the patient’s liver function will gradually recover. In addition, for patients with viral hepatitis, in addition to hepatoprotective therapy, patients should also actively consider antiviral therapy if they are in the viral replication phase.